{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:16:33Z","timestamp":1773850593787,"version":"3.50.1"},"reference-count":88,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.chest.2022.02.007","type":"journal-article","created":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T15:40:20Z","timestamp":1644680420000},"page":"66-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Managing Pulmonary Infection in Adults With Cystic Fibrosis"],"prefix":"10.1016","volume":"162","author":[{"given":"Heather D.","family":"Green","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.chest.2022.02.007_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.chest.2022.02.007_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ppul.1950190103","article-title":"Effects of Pseudomonas aeruginosa colonisation on lung function and anthropomorphic variables in children with cystic fibrosis","volume":"19","author":"Pamukcu","year":"1995","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.chest.2022.02.007_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ppul.1950100210","article-title":"Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti-Pseudomonas aeruginosa antibody levels and pulmonary function","volume":"10","author":"Winnie","year":"1991","journal-title":"Paediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.chest.2022.02.007_bib4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ppul.23036","article-title":"Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis","volume":"50","author":"Zemanick","year":"2015","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.chest.2022.02.007_bib5","unstructured":"Antibiotic Treatment For Cystic Fibrosis Report of the UK Cystic Fibrosis Trust Antibiotic Working Group Report of the UK Cystic Fibrosis Trust Antibiotic Working Group. CF Trust 2009. Accessed May 4, 2022. www.cysticfibrosis.org.uk"},{"issue":"10","key":"10.1016\/j.chest.2022.02.007_bib6","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1513\/AnnalsATS.201404-166OC","article-title":"Cystic Fibrosis Foundation pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection","volume":"11","author":"Mogayzel","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.chest.2022.02.007_bib7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J\u00a0Cyst Fibros"},{"issue":"9","key":"10.1016\/j.chest.2022.02.007_bib9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archpediatrics.2011.136","article-title":"Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"165","author":"Treggiari","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"10","key":"10.1016\/j.chest.2022.02.007_bib10","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2213-2600(20)30331-3","article-title":"Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial","volume":"8","author":"Hewer","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.chest.2022.02.007_bib11","unstructured":"Cystic Fibrosis Foundation Patient Registry 2019 Annual Data Report."},{"issue":"7","key":"10.1016\/j.chest.2022.02.007_bib12","first-page":"CD009650","article-title":"Interventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis","volume":"7","author":"Lo","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 6","key":"10.1016\/j.chest.2022.02.007_bib13","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jpeds.2009.09.001","article-title":"Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis","volume":"155","author":"Borowitz","year":"2009","journal-title":"J\u00a0Pediatr"},{"issue":"11","key":"10.1016\/j.chest.2022.02.007_bib15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/ppul.20914","article-title":"The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis","volume":"43","author":"Sawicki","year":"2008","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.chest.2022.02.007_bib16","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200802-327OC","article-title":"Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis","volume":"178","author":"Dasenbrook","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"23","key":"10.1016\/j.chest.2022.02.007_bib17","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.2010.791","article-title":"Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis","volume":"303","author":"Dasenbrook","year":"2010","journal-title":"J\u00a0Am Med Assoc"},{"issue":"4","key":"10.1016\/j.chest.2022.02.007_bib18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/thoraxjnl-2016-208949","article-title":"Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial","volume":"72","author":"Muhlebach","year":"2017","journal-title":"Thorax"},{"issue":"11","key":"10.1016\/j.chest.2022.02.007_bib19","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/thx.2003.017210","article-title":"Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis","volume":"59","author":"Jones","year":"2004","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.chest.2022.02.007_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jcf.2004.01.005","article-title":"Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults","volume":"3","author":"Courtney","year":"2004","journal-title":"J\u00a0Cyst Fibros"},{"issue":"8","key":"10.1016\/j.chest.2022.02.007_bib21","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/thx.2007.089458","article-title":"Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres","volume":"63","author":"Boussaud","year":"2008","journal-title":"Thorax"},{"key":"#cr-split#-10.1016\/j.chest.2022.02.007_bib22.1","unstructured":"UK Cystic Fibrosis Registry 2019 Annual Data Report"},{"key":"#cr-split#-10.1016\/j.chest.2022.02.007_bib22.2","unstructured":"CF Trust 2019. Accessed May 4, 2022. https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2020-12\/2019%20Registry%20Annual%20Data%20report_Sep%202020.pdf"},{"issue":"4","key":"10.1016\/j.chest.2022.02.007_bib23","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1099\/jmm.0.000458","article-title":"Prevalence of Burkholderia species, including members of Burkholderia cepacia complex, among UK cystic and non-cystic fibrosis patients","volume":"66","author":"Kenna","year":"2017","journal-title":"J\u00a0Med Microbiol"},{"issue":"4","key":"10.1016\/j.chest.2022.02.007_bib24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1164\/rccm.200712-1834OC","article-title":"Impact of burkholderia infection on lung transplantation in cystic fibrosis","volume":"178","author":"Murray","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2022.02.007_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1399-3062.2012.00726.x","article-title":"Fatal Burkholderia gladioli infection misidentified as Empedobacter brevis in a lung transplant recipient with cystic fibrosis","volume":"14","author":"Brizendine","year":"2012","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"10.1016\/j.chest.2022.02.007_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jcf.2006.10.007","article-title":"Burkholderia gladioli: five year experience in a cystic fibrosis and lung transplantation center","volume":"6","author":"Kennedy","year":"2007","journal-title":"J\u00a0Cyst Fibros"},{"issue":"18","key":"10.1016\/j.chest.2022.02.007_bib27","article-title":"Can early Burkholderia cepacia complex infection in cystic fibrosis be eradicated with antibiotic therapy?","volume":"1","author":"Horsley","year":"2011","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"10.1016\/j.chest.2022.02.007_bib28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jac\/dkf137","article-title":"Influence of taxonomic status on the in\u00a0vitro antimicrobial susceptibility of the Burkholderia cepacia complex","volume":"50","author":"Nzula","year":"2002","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.chest.2022.02.007_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00766-17","article-title":"In\u00a0vitro activity of ceftolozane-tazobactam and other antimicrobial agents against Burkholderia cepacia complex and Burkholderia gladioli","volume":"61","author":"Mazer","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.chest.2022.02.007_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00590-18","article-title":"In\u00a0vitro susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam","volume":"62","author":"Van Dalem","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.chest.2022.02.007_bib31","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s10096-009-0774-9","article-title":"Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis","volume":"28","author":"Dales","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4 pt 1","key":"10.1016\/j.chest.2022.02.007_bib32","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1164\/ajrccm.161.4.9907147","article-title":"Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia","volume":"161","author":"Aaron","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.chest.2022.02.007_bib33","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jcf.2013.05.009","article-title":"Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients","volume":"12","author":"Stanojevic","year":"2013","journal-title":"J\u00a0Cyst Fibros"},{"issue":"1","key":"10.1016\/j.chest.2022.02.007_bib34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1183\/09031936.03.00007203","article-title":"Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients","volume":"23","author":"Marchac","year":"2004","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.chest.2022.02.007_bib35","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/thx.2003.017707","article-title":"Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis","volume":"59","author":"Goss","year":"2004","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.chest.2022.02.007_bib36","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1164\/rccm.201009-1392OC","article-title":"Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease","volume":"183","author":"Waters","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2022.02.007_bib37","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.2109078","article-title":"Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis","volume":"166","author":"Goss","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2022.02.007_bib38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jcf.2016.06.007","article-title":"Longitudinal study of Stenotrophomonas maltophilia antibody levels and outcomes in cystic fibrosis patients","volume":"16","author":"Wettlaufer","year":"2017","journal-title":"J\u00a0Cyst Fibros"},{"issue":"10","key":"10.1016\/j.chest.2022.02.007_bib39","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/ppul.23781","article-title":"Incident Stenotrophomonas maltophilia infection and lung function decline in cystic fibrosis","volume":"52","author":"Barksy","year":"2017","journal-title":"Paediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.chest.2022.02.007_bib40","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jcf.2011.03.006","article-title":"Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis","volume":"10","author":"Dalb\u00f8ge","year":"2011","journal-title":"J\u00a0Cyst Fibros"},{"issue":"5","key":"10.1016\/j.chest.2022.02.007_bib41","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jcf.2012.12.006","article-title":"Chronic Stenotrophomonas maltophila infection and mortality or lung transplantation in cystic fibrosis patients","volume":"12","author":"Waters","year":"2013","journal-title":"J\u00a0Cyst Fibros"},{"issue":"1","key":"10.1016\/j.chest.2022.02.007_bib42","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1128\/AAC.48.1.168-171.2004","article-title":"Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis","volume":"48","author":"San Gabriel","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.chest.2022.02.007_bib43","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1128\/AAC.02215-12","article-title":"Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from cystic fibrosis patients","volume":"57","author":"Wu","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.chest.2022.02.007_bib44","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1099\/ijsem.0.000473","article-title":"Bordetella bronchialis sp. nov., Bordatella flabilis sp. nov. and Bordatella sputigen sp.nov., isolated from human respiratory specimens, and reclassification of Achromobacter sedminium Zhang et\u00a0al. 2014 as Verticia sedminium gen. nov., comb. nov","volume":"65","author":"Vandamme","year":"2015","journal-title":"Int J Syst Evol Microbiol"},{"issue":"6","key":"10.1016\/j.chest.2022.02.007_bib45","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jcf.2016.02.014","article-title":"Extensive cultivation of soil and water samples yields various pathogens in patients with cystic fibrosis but not Burkholderia multivorans","volume":"15","author":"Peeters","year":"2016","journal-title":"J\u00a0Cyst Fibros"},{"issue":"4","key":"10.1016\/j.chest.2022.02.007_bib46","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1099\/ijsem.0.000872","article-title":"Reclassification of Achromobacter spiritinus Vandamme et\u00a0al. 2013 as a later heterotypic synonym of Achromobacter marplatensis Gomila et\u00a0al. 2011","volume":"66","author":"Vandamme","year":"2016","journal-title":"Int J Syst Evol Microbiol"},{"issue":"1","key":"10.1016\/j.chest.2022.02.007_bib47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1099\/ijsem.0.001566","article-title":"Achromobacter aloeverae sp. nov., isolated from the root of Aloe vera (L.) Burm.f","volume":"67","author":"Kuncharoen","year":"2017","journal-title":"Int J Syst Evol Microbiol Evol Microbiol"},{"issue":"6","key":"10.1016\/j.chest.2022.02.007_bib48","first-page":"428","article-title":"Achromobacter panacis sp. Nov., isolated from rhizosphere of Panax ginseng","volume":"55","author":"Singh","year":"2017","journal-title":"J\u00a0Microbiol"},{"issue":"3","key":"10.1016\/j.chest.2022.02.007_bib49","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jcf.2012.10.002","article-title":"Identification and distribution of Achromobacter species in cystic fibrosis","volume":"12","author":"Spilker","year":"2013","journal-title":"J\u00a0Cyst Fibros"},{"issue":"4","key":"10.1016\/j.chest.2022.02.007_bib50","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jcf.2015.09.005","article-title":"Use of nrda gene sequence clustering to estimate the prevalence of different Achromobacter species among cystic fibrosis patients in the UK","volume":"15","author":"Coward","year":"2016","journal-title":"J\u00a0Cyst Fibros"},{"issue":"4","key":"10.1016\/j.chest.2022.02.007_bib51","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jcf.2015.12.009","article-title":"Distribution of the species of Achromobacter in a French Cystic Fibrosis Centre and multilocus sequence typing analysis reveal the predominance of A. xylosoxidans and clonal relationships between some clinical and environmental isolates","volume":"15","author":"Amoureaux","year":"2016","journal-title":"J\u00a0Cyst Fibros"},{"issue":"5","key":"10.1016\/j.chest.2022.02.007_bib52","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1099\/jmm.0.000499","article-title":"Prevalence and species distribution of Achromobacter sp. Cultured from cystic fibrosis patients attending the Aarhus centre in Denmark","volume":"66","author":"Gade","year":"2017","journal-title":"J\u00a0Med Microbiol"},{"issue":"1","key":"10.1016\/j.chest.2022.02.007_bib53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jcf.2009.10.005","article-title":"Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients","volume":"9","author":"Hansen","year":"2010","journal-title":"J\u00a0Cyst Fibros"},{"issue":"1","key":"10.1016\/j.chest.2022.02.007_bib54","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jcf.2006.05.011","article-title":"Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance","volume":"6","author":"De Baets","year":"2007","journal-title":"J\u00a0Cyst Fibros"},{"issue":"7","key":"10.1016\/j.chest.2022.02.007_bib55","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1128\/JCM.02556-16","article-title":"Prevalence and outcomes of achromobacter species infections in adults with cystic fibrosis: a North American cohort study","volume":"55","author":"Edwards","year":"2017","journal-title":"J\u00a0Clin Microbiol"},{"issue":"9","key":"10.1016\/j.chest.2022.02.007_bib56","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1600-0463.2008.00995.x","article-title":"Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients","volume":"116","author":"Raso","year":"2008","journal-title":"APMIS"},{"issue":"8","key":"10.1016\/j.chest.2022.02.007_bib57","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s10096-011-1182-5","article-title":"Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients","volume":"30","author":"Lambiase","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.chest.2022.02.007_bib58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/ppul.10143","article-title":"Alcaligenes infection in cystic fibrosis","volume":"34","author":"Tan","year":"2002","journal-title":"Pediatr Pulmonol"},{"issue":"11","key":"10.1016\/j.chest.2022.02.007_bib59","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/JCM.39.11.3942-3945.2001","article-title":"Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis","volume":"39","author":"Saiman","year":"2001","journal-title":"J\u00a0Clin Microbiol"},{"issue":"1","key":"10.1016\/j.chest.2022.02.007_bib60","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijantimicag.2009.08.015","article-title":"In\u00a0vitro susceptibility of Achromobacter spp. Isolates: comparison of disk diffusion, Etest and agar dilution methods","volume":"35","author":"Almuzara","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.chest.2022.02.007_bib61","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eimc.2015.05.006","article-title":"Achromobacter xylosoxidans infection in an adult cystic fibrosis unit in MadridInfecci\u00f3n por Achromobacter xylosoxidans en una unidad adulta de fibrosis qu\u00edstica en Madrid","volume":"34","author":"Otero","year":"2016","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"7","key":"10.1016\/j.chest.2022.02.007_bib62","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1099\/jmm.0.001010","article-title":"Investigation of a Pandoraea apista cluster common to adult and paediatric cystic fibrosis patients attending two hospitals in the same city","volume":"68","author":"Kenna","year":"2019","journal-title":"J\u00a0Med Microbiol"},{"issue":"pt 1","key":"10.1016\/j.chest.2022.02.007_bib63","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1099\/jmm.0.47544-0","article-title":"Evaluation of in\u00a0vitro virulence characteristics of the genus Pandoraea in lung epithelial cells","volume":"57","author":"Caraher","year":"2008","journal-title":"J\u00a0Med Microbiol"},{"issue":"pt 3","key":"10.1016\/j.chest.2022.02.007_bib64","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1099\/jmm.0.022657-0","article-title":"Virulence of an emerging respiratory pathogen, genus Pandoraea, in\u00a0vivo and its interactions with lung epithelial cells","volume":"60","author":"Costello","year":"2011","journal-title":"J\u00a0Med Microbiol"},{"issue":"5","key":"10.1016\/j.chest.2022.02.007_bib65","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/ppul.10383","article-title":"Epidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients","volume":"36","author":"J\u00f8rgensen","year":"2003","journal-title":"Pediatr Pulmonol"},{"issue":"11","key":"10.1016\/j.chest.2022.02.007_bib66","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.arbres.2011.06.015","article-title":"Pandoraea sputorum colonization in a patient with cystic fibrosis [in Spanish]","volume":"47","author":"Mart\u00ednez-Lamas","year":"2011","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.chest.2022.02.007_bib67","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1186\/s12879-015-1327-8","article-title":"Epidemic spread of Pandoraea pulmonicola in a cystic fibrosis center","volume":"15","author":"Degand","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.chest.2022.02.007_bib68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12890-017-0373-y","article-title":"First time identification of Pandoraea sputorum from a patient with cystic fibrosis in Argentina: a case report","volume":"17","author":"Martina","year":"2017","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.chest.2022.02.007_bib69","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1128\/JCM.39.5.1819-1826.2001","article-title":"Assignment of CDC weak oxidizer group 2 (WO-2) to the genus Pandoraea and characterization of three new Pandoraea genomospecies","volume":"39","author":"Daneshvar","year":"2001","journal-title":"J\u00a0Clin Microbiol"},{"issue":"11","key":"10.1016\/j.chest.2022.02.007_bib70","doi-asserted-by":"crossref","first-page":"7136","DOI":"10.1128\/AAC.01112-15","article-title":"Intrinsic carbapenem-hydrolyzing oxacillinases from members of the genus Pandoraea","volume":"59","author":"Schneider","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.chest.2022.02.007_bib71","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3201\/eid0807.010472","article-title":"Infection by Ralstonia species in cystic fibrosis patients: identification of R. pickettii and R. mannitolilytica by polymerase chain reaction","volume":"8","author":"Coenye","year":"2002","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.chest.2022.02.007_bib72","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1099\/ijs.0.02555-0","article-title":"Classification of Ralstonia pickettii-like isolates from the environment and clinical samples as Ralstonia insidiosa sp. nov","volume":"53","author":"Coenye","year":"2003","journal-title":"Int J Syst Evol Microbiol"},{"issue":"pt 9","key":"10.1016\/j.chest.2022.02.007_bib73","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1099\/ijs.0.066712-0","article-title":"Polyphasic taxonomic revision of the Ralstonia solanacearum species complex: proposal to emend the descriptions of Ralstonia solanacearum and Ralstonia syzygii and reclassify current R. syzygii strains as Ralstonia syzygii subsp. syzygii subsp. nov., R. s","volume":"64","author":"Safni","year":"2014","journal-title":"Int J Syst Evol Microbiol"},{"issue":"7","key":"10.1016\/j.chest.2022.02.007_bib74","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1128\/JCM.43.7.3463-3466.2005","article-title":"Use of PCR analyses to define the distribution of Ralstonia species recovered from patients with cystic fibrosis","volume":"43","author":"Coenye","year":"2005","journal-title":"J\u00a0Clin Microbiol"},{"issue":"13","key":"10.1016\/j.chest.2022.02.007_bib75","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1017\/S0950268817001728","article-title":"Ralstonia infection in cystic fibrosis","volume":"145","author":"Green","year":"2017","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.chest.2022.02.007_bib76","first-page":"48","article-title":"Ralstonia mannitolilytica in cystic fibrosis: a new predictor of worse outcomes","volume":"20","author":"Coman","year":"2017","journal-title":"Respir Med Case Reports"},{"key":"10.1016\/j.chest.2022.02.007_bib77","first-page":"1025","article-title":"The antibiotic susceptibility of water-based bacteria Ralstonia pickettii and Ralstonia insidiosa","volume":"62","author":"Ryan","year":"2013","journal-title":"J\u00a0Microbiol"},{"issue":"8","key":"10.1016\/j.chest.2022.02.007_bib78","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1128\/AAC.00072-12","article-title":"Combination antimicrobial susceptibility testing of multidrug-resistant Stenotrophomonas maltophilia from cystic fibrosis patients","volume":"56","author":"Milne","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.chest.2022.02.007_bib79","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01595-19","article-title":"In\u00a0vitro activities of \u03b2-lactam\u2013\u03b2-lactamase inhibitor antimicrobial agents against cystic fibrosis respiratory pathogens","volume":"64","author":"Caverly","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.chest.2022.02.007_bib80","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01968-17","article-title":"In\u00a0vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.chest.2022.02.007_bib81","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/thoraxjnl-2015-207983","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.chest.2022.02.007_bib82","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jcf.2013.08.011","article-title":"Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial","volume":"13","author":"Tullis","year":"2014","journal-title":"J\u00a0Cyst Fibros"},{"issue":"13","key":"10.1016\/j.chest.2022.02.007_bib83","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"J\u00a0Am Med Assoc"},{"issue":"201","key":"10.1016\/j.chest.2022.02.007_bib84","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1164\/rccm.201906-1206OC","article-title":"Pulmonary outcomes associated with long-term azithromycin therapy in cystic fibrosis","volume":"4","author":"Nichols","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2022.02.007_bib85","series-title":"Standardized treatment of pulmonary exacerbations II (STOP2). NCT02781610. ClinicalTrials.gov","year":"2016"},{"issue":"1","key":"10.1016\/j.chest.2022.02.007_bib86","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1378\/chest.130.1.222","article-title":"Aspergillus bronchitis in cystic fibrosis","volume":"130","author":"Shoseyov","year":"2006","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2022.02.007_bib87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036077","article-title":"Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study","volume":"7","author":"Aaron","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.chest.2022.02.007_bib88","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1128\/JCM.00432-15","article-title":"Rapid detection of emerging pathogens and loss of microbial diversity associated with severe lung disease in cystic fibrosis","volume":"53","author":"Flight","year":"2015","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.chest.2022.02.007_bib89","series-title":"Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified (CFMATTERS). NCT02526004 ClinicalTrials.gov","year":"2016"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369222002513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369222002513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:15:12Z","timestamp":1746836112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369222002513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0012369222002513"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2022.02.007","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing Pulmonary Infection in Adults With Cystic Fibrosis","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2022.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}